Literature DB >> 23537753

Advances in stem cell therapy against gliomas.

M Sarah S Bovenberg1, M Hannah Degeling, Bakhos A Tannous.   

Abstract

Malignant gliomas are one of the most lethal cancers, and despite extensive research very little progress has been made in improving prognosis. Multimodality treatment combining surgery, radiation, and chemotherapy is the current gold standard, but effective treatment remains difficult due to the invasive nature and high recurrence of gliomas. Stem cell-based therapy using neural, mesenchymal, or hematopoietic stem cells may be an alternative approach because it is tumor selective and allows targeted therapy that spares healthy brain tissue. Stem cells can be used to establish a long-term antitumor response by stimulating the immune system and delivering prodrug, metabolizing genes, or oncolytic viruses. In this review, we discuss current trends and the latest developments in stem cell therapy against malignant gliomas from both the experimental laboratory and the clinic.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23537753     DOI: 10.1016/j.molmed.2013.03.001

Source DB:  PubMed          Journal:  Trends Mol Med        ISSN: 1471-4914            Impact factor:   11.951


  21 in total

1.  Dying glioma cells establish a proangiogenic microenvironment through a caspase 3 dependent mechanism.

Authors:  Xiao Feng; Yang Yu; Sijia He; Jin Cheng; Yanping Gong; Zhengxiang Zhang; Xuguang Yang; Bing Xu; Xinjian Liu; Chuan-Yuan Li; Ling Tian; Qian Huang
Journal:  Cancer Lett       Date:  2016-11-05       Impact factor: 8.679

Review 2.  The blood-brain barrier and blood-tumour barrier in brain tumours and metastases.

Authors:  Costas D Arvanitis; Gino B Ferraro; Rakesh K Jain
Journal:  Nat Rev Cancer       Date:  2019-10-10       Impact factor: 60.716

3.  Chemical induction of unfolded protein response enhances cancer cell killing through lytic virus infection.

Authors:  Vibhu Prasad; Maarit Suomalainen; Mirjam Pennauer; Artur Yakimovich; Vardan Andriasyan; Silvio Hemmi; Urs F Greber
Journal:  J Virol       Date:  2014-09-03       Impact factor: 5.103

Review 4.  The multifaceted mechanisms of malignant glioblastoma progression and clinical implications.

Authors:  Rui Sun; Albert H Kim
Journal:  Cancer Metastasis Rev       Date:  2022-08-03       Impact factor: 9.237

5.  Systemic anticancer neural stem cells in combination with a cardiac glycoside for glioblastoma therapy.

Authors:  Jian Teng; Seyedali Hejazi; Christian E Badr; Bakhos A Tannous
Journal:  Stem Cells       Date:  2014-08       Impact factor: 6.277

6.  Nucleolar and spindle-associated protein 1 is a tumor grade correlated prognosis marker for glioma patients.

Authors:  Tao Zhu; Pan Xie; Yuan-Feng Gao; Ma-Sha Huang; Xi Li; Wei Zhang; Hong-Hao Zhou; Zhao-Qian Liu
Journal:  CNS Neurosci Ther       Date:  2018-01-15       Impact factor: 5.243

7.  Olfactory Ensheathing Cells: A Trojan Horse for Glioma Gene Therapy.

Authors:  Litia A Carvalho; Jian Teng; Renata L Fleming; Elie I Tabet; Max Zinter; Ricardo A de Melo Reis; Bakhos A Tannous
Journal:  J Natl Cancer Inst       Date:  2019-03-01       Impact factor: 13.506

Review 8.  Evolving Drug Delivery Strategies to Overcome the Blood Brain Barrier.

Authors:  David S Hersh; Aniket S Wadajkar; Nathan Roberts; Jimena G Perez; Nina P Connolly; Victor Frenkel; Jeffrey A Winkles; Graeme F Woodworth; Anthony J Kim
Journal:  Curr Pharm Des       Date:  2016       Impact factor: 3.116

Review 9.  Drug delivery strategies to enhance the permeability of the blood-brain barrier for treatment of glioma.

Authors:  Fang Zhang; Chun-Lei Xu; Chun-Mei Liu
Journal:  Drug Des Devel Ther       Date:  2015-04-09       Impact factor: 4.162

10.  In vivo near-infrared imaging for the tracking of systemically delivered mesenchymal stem cells: tropism for brain tumors and biodistribution.

Authors:  Seong Muk Kim; Chang Hyun Jeong; Ji Sun Woo; Chung Heon Ryu; Jeong-Hwa Lee; Sin-Soo Jeun
Journal:  Int J Nanomedicine       Date:  2015-12-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.